Becton, Dickinson and Company (NYSE:BDX) had its price target boosted by investment analysts at Morgan Stanley from $205.00 to $245.00 in a report issued on Friday. The brokerage currently has an “equal weight” rating on the medical instruments supplier’s stock. Morgan Stanley’s price objective indicates a potential upside of 9.17% from the company’s current price.

Several other brokerages have also recently weighed in on BDX. Royal Bank Of Canada upped their price target on shares of Becton, Dickinson and from $210.00 to $230.00 and gave the stock a “sector perform” rating in a research report on Friday. Wells Fargo & Company reaffirmed a “positive” rating and issued a $235.00 price target (up previously from $225.00) on shares of Becton, Dickinson and in a research report on Tuesday, October 24th. They noted that the move was a valuation call. Zacks Investment Research raised shares of Becton, Dickinson and from a “sell” rating to a “hold” rating in a research report on Friday, October 20th. Bank of America Corporation reaffirmed a “buy” rating and issued a $225.00 price target (up previously from $200.00) on shares of Becton, Dickinson and in a research report on Friday, July 21st. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and issued a $213.00 price target on shares of Becton, Dickinson and in a research report on Tuesday, September 12th. Five research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $209.73.

Becton, Dickinson and (NYSE:BDX) last released its quarterly earnings data on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.37 by $0.03. The company had revenue of $3.17 billion during the quarter, compared to analysts’ expectations of $3.14 billion. Becton, Dickinson and had a net margin of 8.52% and a return on equity of 22.51%. The firm’s quarterly revenue was down 2.0% on a year-over-year basis. During the same period in the previous year, the company earned $2.12 EPS.

COPYRIGHT VIOLATION NOTICE: “Becton, Dickinson and Company (BDX) Given New $245.00 Price Target at Morgan Stanley” was originally reported by Watch List News and is the property of of Watch List News. If you are accessing this piece on another website, it was illegally copied and republished in violation of international copyright & trademark laws. The original version of this piece can be accessed at https://www.watchlistnews.com/becton-dickinson-and-company-bdx-given-new-245-00-price-target-at-morgan-stanley/1676161.html.

In other Becton, Dickinson and news, insider Thomas E. Polen, Jr. sold 5,971 shares of the company’s stock in a transaction that occurred on Wednesday, August 9th. The shares were sold at an average price of $197.41, for a total transaction of $1,178,735.11. Following the transaction, the insider now owns 12,861 shares in the company, valued at approximately $2,538,890.01. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Gary M. Cohen sold 15,512 shares of the company’s stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $203.77, for a total transaction of $3,160,880.24. Following the transaction, the insider now owns 95,781 shares in the company, valued at approximately $19,517,294.37. The disclosure for this sale can be found here. Insiders have sold a total of 75,904 shares of company stock worth $15,242,688 in the last 90 days. 1.40% of the stock is currently owned by company insiders.

A number of institutional investors have recently modified their holdings of BDX. Almanack Investment Partners LLC. acquired a new stake in shares of Becton, Dickinson and in the first quarter worth $105,000. Mitsubishi UFJ Securities Holdings Co. Ltd. increased its stake in shares of Becton, Dickinson and by 55.8% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 670 shares of the medical instruments supplier’s stock worth $131,000 after acquiring an additional 240 shares during the period. Parkside Financial Bank & Trust increased its stake in shares of Becton, Dickinson and by 8.1% in the second quarter. Parkside Financial Bank & Trust now owns 684 shares of the medical instruments supplier’s stock worth $133,000 after acquiring an additional 51 shares during the period. Harfst & Associates Inc. increased its stake in shares of Becton, Dickinson and by 46.4% in the second quarter. Harfst & Associates Inc. now owns 697 shares of the medical instruments supplier’s stock worth $135,000 after acquiring an additional 221 shares during the period. Finally, Financial Architects Inc increased its stake in shares of Becton, Dickinson and by 8.0% in the second quarter. Financial Architects Inc now owns 731 shares of the medical instruments supplier’s stock worth $142,000 after acquiring an additional 54 shares during the period. Institutional investors and hedge funds own 86.70% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Analyst Recommendations for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.